Resolution of heart failure in patients with AL amyloidosis

Annals of Internal Medicine

Volumn 125, Issue 6, 1996, Pages 481-484

  Dubrey, Simon ^a   Mendes, Lisa ^a   Skinner, Martha ^a   Falk, Rodney H ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; MELPHALAN;

AMYLOIDOSIS; ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; DOPPLER ECHOCARDIOGRAPHY; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; REMISSION;

AMYLOIDOSIS; COLCHICINE; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; REMISSION INDUCTION;

EID: 0030587249     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-6-199609150-00009     Document Type: Article

References (18)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1996;32:45-59.
2. Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978;52:818-27.
3. Skinner M, Anderson JJ, Simms R, Falk R, Wang M. Libbey CA, et al. Treatment of 100 patients with primary (AL) amyloidosis: a randomized trial of melphalan, prednisone, and colchidne vs colchicine only. Am J Med. 1996;100:290-8.
4. Buxbaum JN, Hurley ME, Chuba J, Spiro T. Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone. Am J Med. 1979;67:867-78.
5. Gertz MA, Kyle RA. Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature. Mayo Clin Proc. 1986;61:218-23.
6. Kaufman BM. Primary amyloidosis, paraproteinaemia and neuropathy. Proc R Soc Med. 1976;69:707-8.
7. Fritz DA, Luggen ME, Hess EV. Unusual longevity in primary systemic amyloidosis: a 19-year survivor. Am J Med. 1989;86:245-8.
8. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood. 1991;77:257-62.
9. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49:9-13.
10. Bradstock K, Clancy R, Uther J, Basten A, Richards J. The successful treatment of primary amyloidosis with intermittent chemotherapy. Aust N Z J Med. 1978;8:176-9.
11. Brown MP, Walls RS. Amyloidosis of immunoglobulin origin: useful treatment? Med J Aust. 1990;152:95-7.
12. Kyle RA, Wagoner RD, Holley KE. Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone. Arch Intern Med. 1982;142:1445-7.
13. Kiprov DD, Miller RG. Polymyositis associated with monoclonal gammopathy. Lancet. 1984;2:1183-6.
14. Prado MJ, Nicastri AL, Leo P, Uchino E, Sesso A, Marcondes M, et al. Nephrotoxicity of human Bence Jones protein in rats: proteinuria and enzymuria profile. Braz J Med Biol Res. 1993;26:633-8.
15. Ledingham JG. Tubular toxicity of filtered proteins. Am J Nephrol. 1990;10 (Suppl 1):52-7.
16. Lowenstein J, Gallo G. Remission of the nephrotic syndrome in renal amyloidosis. N Engl J Med. 1970;282:128-32.
17. Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. Am J Med. 1985;79:708-16.
18. Skinner M, Anderson J, Wang M, Simms R, Falk R, Jones LA, et al. Treatment of patients with primary amyloidosis. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID, eds. Amyloid and Amyloidosis: The Proceedings of the VIIth International Symposium on Amyloidosis, July 11-15, 1993, Kingston, Ontario, Canada. New York: Parthenon; 1994: 232-4.